Mitochondria-derived methylmalonic acid aggravates ischemia–reperfusion injury by activating reactive oxygen species-dependent ferroptosis

Junchen Guo,Shanjie Wang,Xin Wan,Xiaoxuan Liu,Zeng Wang,Chenchen Liang,Zhenming Zhang,Ye Wang,Miao Yan,Pengyan Wu,Shaohong Fang,Bo Yu
DOI: https://doi.org/10.1186/s12964-024-01479-z
IF: 7.525
2024-01-19
Cell Communication and Signaling
Abstract:Ferroptosis is a regulatory cell death process pivotal in myocardial ischemia–reperfusion (I/R) injury. However, the precise mechanism underlying myocardial ferroptosis remains less known. In this study, we investigated the pathophysiological mechanisms of methylmalonic acid (MMA) associated with ferroptosis activation in cardiomyocytes after I/R. We found an increase level of MMA in patients with acute myocardial injury after reperfusion and AC16 cells under hypoxia/reoxygenation (H/R) condition. MMA treatment was found to be associated with excessive oxidative stress in cardiomyocytes, leading to ferroptosis-related myocardial injury. In mice with I/R injury, MMA treatment aggravated myocardial oxidative stress and ferroptosis, which amplified the myocardial infarct size and cardiac dysfunction. Mechanistically, MMA promoted NOX2/4 expression to increase reactive oxygen species (ROS) production in cardiomyocytes, aggravating myocardial injury. Notably, the increased ROS further activated ferroptosis by inhibiting solute carrier family 7 member 11 (SLC7A11) and glutathione peroxidase 4 (GPX4) expression. In addition, MMA decreased the ectopic nuclear distribution of nuclear factor E2-related factor 2 (NRF2) by increasing the interaction between NRF2 and kelch-like ECH-associated protein 1 (KEAP1). This impeded the activation of GPX4/SLC7A11, downstream of NRF2, activating ferroptosis and aggravating myocardial cell injury. Collectively, our study indicates that MMA activates oxidative stress and ROS generation, which induces ferroptosis to exacerbate cardiomyocyte injury in an I/R model. These findings may provide a new perspective for the clinical treatment of I/R injury and warrant further investigation.
cell biology
What problem does this paper attempt to address?
The paper aims to explore the specific mechanisms by which methylmalonic acid (MMA) activates the ferroptosis pathway in myocardial ischemia-reperfusion (I/R) injury. The main research contents include: 1. **Background and Significance**: Acute myocardial infarction (AMI) is a major health risk worldwide. Although percutaneous coronary intervention (PCI) can reopen occluded vessels, it can trigger myocardial ischemia-reperfusion injury. Ferroptosis is a novel form of programmed cell death associated with the development of various diseases. However, the exact mechanisms of myocardial ferroptosis are not fully understood. 2. **Core Issue**: Researchers have found that MMA levels significantly increase during myocardial ischemia-reperfusion injury. Therefore, they studied how MMA induces ferroptosis by increasing reactive oxygen species (ROS) production and exacerbates myocardial cell damage. 3. **Experimental Design and Results**: - In vitro experiments using AC16 cardiomyocytes under hypoxia-reoxygenation (H/R) conditions showed that MMA treatment led to decreased cell viability. - In vivo experiments, where mice were injected with MMA and subjected to I/R surgery, revealed that MMA treatment exacerbated myocardial oxidative stress and ferroptosis, increased myocardial infarct size, and caused cardiac dysfunction. - Mechanistically, MMA increased ROS production by promoting NOX2/4 expression, further inhibiting the expression of antioxidant proteins SLC7A11 and GPX4, thereby activating ferroptosis. - Additionally, MMA enhanced the interaction between KEAP1 and NRF2, reducing the nuclear distribution of NRF2 and hindering the activation of its downstream genes GPX4/SLC7A11. In summary, this study reveals the mechanism by which MMA induces ferroptosis by activating ROS production, thereby exacerbating myocardial cell damage, providing a new perspective for the clinical treatment of myocardial ischemia-reperfusion injury.